Amicus Therapeutics Stock News

PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a

Although AT-GAA failed a phase 3 trial, there are reasons it could be approved.

Amicus Therapeutics Inc. ( FOLD , Financial) is the poster child for the malaise affecting small biotechs, especially those working on gene and cell therapy. Owners of the stock are hoping the company

Amicus Therapeutics Inc (NASDAQ: FOLD ) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up to 36 months showed persistent and durable effects on six-minute walk test (6MWT) distance and other measures of motor function and … Full story available on Benzinga.com

Amicus Therapeutics (FOLD) reported additional results from a global phase 1/2 study (ATB200-02) of AT-GAA in adult patients with Pompe disease.Pompe disease is an inherited…

Amicus Therapeutics Inc (NASDAQ: FOLD) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will

The trading price of Amicus Therapeutics Inc. (NASDAQ:FOLD) floating higher at last check on Wednesday, March 09, closing at $9.05, 8.19% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it … Amicus Therapeutics Inc.’s Stock Gains 8.19%, But It May Still Be Worth Investing In. Read More »

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42 nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T.

Global Batten Disease Drug Pipeline Market Research Report provides key analysis on the market status of the Batten Disease Drug Pipeline with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe.

Amicus Therapeutics called off a planned spinout of its gene therapy division via a combination with a SPAC, spelling more trouble for the gene therapy field.

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2021 Results - Earnings Call Transcript